Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not listed Phase 2 Interventional

Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor

ClinicalTrials.gov ID: NCT02724527

Public ClinicalTrials.gov record NCT02724527. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 8:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 for Efficacy and Safety in Patients With CF Heterozygous for F508del-CFTR + Gating Mutation Being Treated With Ivacaftor

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Cavosonstat (N91115) is being studied as a potential novel therapy for cystic fibrosis (CF), and this study assesses a target population of patients who are heterozygous for F508del-CFTR and a gating mutation that is approved for treatment with ivacaftor (G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R).

Study identification

NCT ID
NCT02724527
Recruitment status
Not listed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Nivalis Therapeutics, Inc.
Industry
Enrollment
19 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2016
Primary completion
Mar 31, 2017
Completion
Mar 31, 2017
Last update posted
Nov 20, 2016

2016 – 2017

United States locations

U.S. sites
12
U.S. states
10
U.S. cities
12
Facility City State ZIP Site status
National Jewish Health Denver Colorado 80206
Johns Hopkins Hospital Baltimore Maryland 21287
Boston Children's Hospital Boston Massachusetts 02115
Washington University St Louis Missouri 63110
Columbia University New York New York 10032
Cincinnati Children's Hospital Cincinnati Ohio 45229
Rainbow Babies and Children's Hospital - Case Medical Center Cleveland Ohio 44106
Nationwide Children's Hospital Columbus Ohio 43205
Oregon Health and Science University Portland Oregon 97239
Children's Hospital Pittsburgh Pittsburgh Pennsylvania 15224
University of Utah Salt Lake City Utah 84132
Medical Center of Wisconsin Madison Wisconsin 53792

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Recently updated Cystic Fibrosis trials

Other public records listing Cystic Fibrosis. Sorted by last update posted; newest first. Not a recommendation.

All Cystic Fibrosis trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02724527, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 20, 2016 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02724527 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →